[1] 孟化民.乳腺癌易感基因相关蛋白1(BAP1)在胃癌组织中的表达及临床意义[J].吉林医学,2021,42(10):2484-2485.
[2] LIU Y, CHEN X, CHEN X, et al. High SALM3 expression in tumor cells and fibroblasts is correlated with poor prognosis in gastric cancer patients[J].Dis Markers, 2019,2019(Pt.2):1-8.
[3] 董林,齐笛,何佳婧,等.血清肿瘤标志物对胃癌患者术后复发转移的预测价值及影响因素分析[J].癌症进展,2021,19(8):798-801.
[4] 王磊,辛小敏,闫小燕,等.胃癌组织中胎盘特异性基因1在不同部位的表达与临床病理特征及预后的关系[J].实用癌症杂志,2022,37(5):712-715.
[5] ZHAO P, MA W, HU Z, et al. Up-regulation of miR-340-5p promotes progression of thyroid cancer by inhibiting BMP4[J].J Endocrinol Invest, 2018, 41(10):1165-1172.
[6] 王娟,张婕,纪孝联.miR-1915-3p在胃癌细胞中的表达水平及其对胃癌细胞增殖和凋亡的影响[J].安徽医学,2020,41(8):876-879.
[7] 邢智伟,乔晓娟,马补换,等.miR-340通过靶向GRP78促进结直肠癌细胞凋亡并抑制其增殖、迁移和侵袭[J].中国生物化学与分子生物学报,2021,37(4):516-523.
[8] ZHOU W, LIU Y, GAO Y, et al. MICAL2 is a novel nucleocytoplasmic shuttling protein promoting cancer invasion and growth of lung adenocarcinoma[J].Cancer Lett, 2020, 28(483): 75-86.
[9] 姚军.CIAPIN1和P-gp蛋白在胃癌组织中的表达及临床意义[J].当代医学,2021,27(13):92-94.
[10] 岳宏宇,陈平,丛春莉,等.miRNA在胃癌的发病机制及诊治方面的研究进展[J].内蒙古医科大学学报,2020,42(3):325-328.
[11] 顾俊骏,方德宁,袁洁璐,等.MACC1、SPON2在胃癌组织中的表达及其临床意义[J].中国癌症防治杂志,2021,13(3):272-276.
[12] 范文洁,陈象逊,周梦熙,等.基于数据挖掘分析RASAL2在胃癌中的表达及其临床意义[J].安徽医学,2021,42(10):1118-1122.
[13] 赵鹤,魏晓敏,尹素凤.1988—2017年中国居民胃癌死亡趋势分析[J].实用预防医学,2020,27(12):1468-1471.
[14] 任彦红,孙建红,侯世科,等.基于TCGA数据库探讨胃癌组织中miR-96、BDNF表达变化和临床病理意义[J].解放军医药杂志,2020,32(4):24-28.
[15] 赵小蕾,陈应坚,廖苑君,等.胃癌相关mRNA和miRNA融合网络构建及关键节点分析[J].中华肿瘤防治杂志,2020,27(8):612-618.
[16] 高铭,杨春宇,王彤,等.lncRNA和miRNA在胃癌中的研究进展[J].中国老年学杂志,2021,41(17):3853-3858.
[17] SONG L, DUAN P, GAN Y, et al. MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATβ in osteosarcoma[J].Braz J Med Biol Res, 2017, 50(5):1-9.
[18] 王妹兴,印季良,肖谜,等.结肠癌组织中miR-340和CCND1表达及临床意义[J].临床肿瘤学杂志,2019, 24(6):538-542.
[19] XIAO C, HONG H, YU H, et al. MiR-340 affects gastric cancer cell proliferation, cycle, and apoptosis through regulating SOCS3/JAK-STAT signaling pathway[J].Immunopharmacol Immunotoxicol, 2018, 40(4):278-283.
[20] CAI Y, LU J, TANG F. Overexpression of MICAL2, a novel tumor-promoting factor, accelerates tumor progression through regulating cell proliferation and EMT[J].J Cancer, 2018, 9(3):521-527.
[21] BARRAVECCHIA I, MARIOTTI S, PUCCI A, et al. MICAL2 is expressed in cancer associated neo-angiogenic capillary endothelia and it is required for endothelial cell viability, motility and VEGF response[J].Biochim Biophys Acta Mol Basis Dis, 2019, 1865(9):2111-2124. |